News

Mirum’s LIVMARLI Now FDA Approved in Tablet Formulation
LIVMARLI Tablet formulation approved for patients with Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic ...
Stocktwits on MSN3d
FDA Approves Mirum Pharmaceuticals’ Drug For Rare Liver Disease Patients In Tablet Form: Retail Stays Bullish
Shares of Mirum Pharmaceuticals, Inc. (MIRM) were in the spotlight on Monday after the company announced that the U.S. Food ...
Mirum Pharmaceuticals receives FDA approval for Livmarli tablet formulation
Mirum announced the FDA approved a new tablet formulation of Livmarli for the treatment of cholestatic pruritus in patients with Alagille ...
MPR3d
New Tablet Formulation of Livmarli Gets FDA Approval
The Food and Drug Administration (FDA) has approved a tablet formulation of Livmarli ® (maralixibat).
Nasdaq21d
LIVMARLI Now Approved in Japan for ALGS and PFIC
LIVMARLI is the first and only treatment available for cholestatic pruritus in patients with Alagille syndrome and Progressive Familial Intrahepatic Cholestasis in Japan “We are thrilled to see ...
Seeking Alpha24d
Mirum Pharmaceuticals: Set Fair For Share Price Momentum - Reversing My Sell Call
Mirum markets three drugs: LIVMARLI, Cholbam, and Chenodal, with LIVMARLI showing significant growth in treating cholestatic pruritus in ALGS and PFIC. Mirum's 2024 net product sales reached $336 ...
Business Wire3d
Mirum’s LIVMARLI Now FDA Approved in Tablet Formulation
--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the U.S. Food and Drug Administration (FDA) has approved a new tablet formulation of LIVMARLI ...
Yahoo Finance21d
LIVMARLI Now Approved in Japan for ALGS and PFIC
FOSTER CITY, Calif., March 27, 2025--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that its partner, Takeda Pharmaceutical Company Limited, has received approval by ...